Brief: Aspira Women’s Health Signs Licensing Agreement With Dana Farber Cancer Institute For Development Of MicroRNA-Based Ovarian Cancer Test
11/05/2023 13:44
May 11 (Reuters) - Aspira Women's Health Inc AWH.O :
* ASPIRA WOMEN’S HEALTH SIGNS AN EXCLUSIVE LICENSING
AGREEMENT
WITH DANA FARBER CANCER INSTITUTE FOR THE DEVELOPMENT OF
MICRORNA-BASED OVARIAN CANCER TEST
Source text for Eikon: ID:nGNX8GrjmR
Further company coverage: AWH.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Aspira Women's Health
See all newsBrief: Aspira Women’S Health Announces Receipt Of Delisting Notification From Nasdaq
Brief: Aspira Women's Health On April 4, Enters Equity Purchase Agreement With Triton Funds
Brief: Aspira Women's Health Files For Offering Up To 50 Units, 50 Mln Pre-Funded Units
Brief: Aspira Women's Health Interim CFO John Kallassy Resigns
Brief: Aspira Women's Health Fails To Regain Nasdaq Compliance